Ceisteanna Parlaiminte

Gender Recognition

Paul Murphy

1285. Deputy Paul Murphy asked the Minister for Health what exactly were the actions of hormones a decade later the National Gender Service staff were referring to in a recent radio interview (details supplied). [13907/24]

Gender Recognition

Paul Murphy

1286. Deputy Paul Murphy asked the Minister for Health the names of the clinics in the United States who continue to prescribe puberty blocker monotherapy up to age 28 or 29 which were mentioned by National Gender Service staff in a radio interview (details supplied) [13908/24]

Gender Recognition

Paul Murphy

1287. Deputy Paul Murphy asked the Minister for Health if the National Gender Service can confirm they believe that the Tavistock and Antwerp clinics had prescribed hormones on the basis of a single phone call as indicated in a recent radio interview (details supplied). [13909/24]

Gender Recognition

Paul Murphy

1288. Deputy Paul Murphy asked the Minister for Health to clarify if the National Gender Service staff believe that you need to fully know your sexual orientation in order to access transgender medical interventions as indicated in a recent radio interview (details supplied). [13910/24]

Gender Recognition

Paul Murphy

1289. Deputy Paul Murphy asked the Minister for Health if the National Gender Service can share the evidence base for sexual attraction being delayed in neurodiverse individuals and its relevance in trans medicine as indicated in a recent radio interview (details supplied). [13911/24]

Gender Recognition

Paul Murphy

1290. Deputy Paul Murphy asked the Minister for Health to clarify exactly what the "clear evidence of harm from current practice to significant numbers of vulnerable children" that was referenced by National Gender Service staff in a recent radio interview (details supplied) is. [13912/24]

Gender Recognition

Paul Murphy

1291. Deputy Paul Murphy asked the Minister for Health if the National Gender Service considers trans patient groups to be expressing an ideological position when advocating for informed consent healthcare in line with the World Professional Association for Transgender Health, WPATH. [13913/24]

Departmental Investigations

Paul Murphy

1307. Deputy Paul Murphy asked the Minister for Health if there is a department which investigates issues of safeguarding of a vulnerable adult; and if he will provide the details of supports available to a person (details supplied). [14023/24]

Health Services

Paul Murphy

1315. Deputy Paul Murphy asked the Minister for Health the spring due to be removed from a patient (details supplied) at Temple Street Hospital will be retained for examination; and if so, what examination will be conducted. [14059/24]

Healthcare Policy

Paul Murphy

1456. Deputy Paul Murphy asked the Minister for Health if one parent or guardian objects to therapy for a child, if this means that the child is not permitted to see a therapist; if so, if the Minister will consider issuing a guideline similar to the UK's National Health Service, NHS, that is where the consent of only one parent is necessary (details supplied); and if he will make a statement on the matter. [14658/24]

Health Services

Paul Murphy

1514. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 1334 of 20 March 2024, if the National Gender Service does not follow the 2017 "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline" when considering dosages and hormone levels. [14898/24]

Health Services

Paul Murphy

1515. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 1334 of 20 March 2024, if the National Gender Service does not use any biochemical reference ranges for hormones for patients in their care. [14899/24]

Health Services

Paul Murphy

1516. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 1334 of 20 March 2024, if there are any circumstances where National Gender Service would consider oestradiol levels in a trans woman below 100 pmol/L or above 600 pmol/L to be of any concern. [14900/24]

Health Services

Paul Murphy

1517. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 1334 of 20 March 2024, if the National Gender Service can provide an example scenario, including specific hormone levels, where "hormone levels can be measure to guide treatment decisions in some scenarios, such as requests to increase hormone doses. [14901/24]

Health Services

Paul Murphy

1518. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 1334 of 20 March 2024, if the National Gender Service agrees that advising GPs not to provide hormone blood tests will prevent other medical teams from having information they might need for dosage increases. [14902/24]

Health Services

Paul Murphy

1519. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 1334 of 20 March 2024, if the National Gender Service agrees that clinicians outside their services can use their own clinical judgement when it comes to target to treat approaches and biochemical reference ranges. [14903/24]

Health Services

Paul Murphy

1520. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 1334 of 20 March 2024, what the National Gender Service advises for trans patients on hormones with other services who are unable to access hormone level blood tests. [14904/24]

Health Services

Paul Murphy

1521. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 560 of 20 February 2024, to ask the National Gender Service if the referenced paper underlies their model of care. [14905/24]

Health Services

Paul Murphy

1522. Deputy Paul Murphy asked the Minister for Health if the National Gender Service is aware of EMA/147755/2020 "restrictions in use of cyproterone due to meningioma risk" and the 2021 paper "Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study"; and what initial dose they use for cyproterone acetate. [14906/24]

Health Services

Paul Murphy

1523. Deputy Paul Murphy asked the Minister for Health when his Department requested the formation of the 2018 IEHG Steering Group for the Development of a National Gender Service; and if he will provide a copy of the request to do so. [14907/24]